This project aims to help patients with myeloproliferative neoplasms (MPN) receive more personalised and effective treatment. Although several treatments exist, including JAK inhibitor drugs, doctors currently lack reliable tools to decide which treatment is best for each patient. Some patients respond well to low-intensity therapies, while others need stronger treatment, but there are no clear biological markers to guide these decisions. As a result, patients may experience unnecessary side effects or limited benefit.

This project will use advanced genetic and molecular data to discover new biomarkers, which are tools that can help guide decisions about which treatments are likely to work best for each person. By combining detailed genetic, protein, and molecular data (“omics” data) with clinical results and patient-reported experiences, the research team will uncover patterns that link specific biological profiles to treatment responses and side effects.

The team will build a unique cohort of MPN patients, collecting samples and data over time to track changes during treatment. Advanced laboratory techniques, including single-cell analysis, will allow researchers to explore disease and drug response at high resolution. Promising biological markers will also be tested as potential new treatment targets.

Finally, the project will assess how to bring these discoveries into clinical practice, addressing technical, regulatory, and market requirements.

Led by the HOPE consortium, a collaboration of clinicians, researchers, patient representatives, and regulatory experts, this project will create the foundation for truly personalised, patient-centred therapy in MPN, helping to choose the right treatment for the right patient at the right time.